{"name":"Saglik Bilimleri Universitesi","slug":"saglik-bilimleri-universitesi","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Myorel","genericName":"Myorel","slug":"myorel","indication":"Other","status":"phase_1"},{"name":"hyoscine-n-butylbromide, ondansetron","genericName":"hyoscine-n-butylbromide, ondansetron","slug":"hyoscine-n-butylbromide-ondansetron","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"NSAID's","genericName":"NSAID's","slug":"nsaid-s","indication":"Mild to moderate pain","status":"marketed"}]}],"pipeline":[{"name":"Myorel","genericName":"Myorel","slug":"myorel","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NSAID's","genericName":"NSAID's","slug":"nsaid-s","phase":"marketed","mechanism":"NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.","indications":["Mild to moderate pain","Fever","Inflammatory conditions (e.g., rheumatoid arthritis, osteoarthritis)","Dysmenorrhea"],"catalyst":""},{"name":"hyoscine-n-butylbromide, ondansetron","genericName":"hyoscine-n-butylbromide, ondansetron","slug":"hyoscine-n-butylbromide-ondansetron","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQSU1nZ0VqM3RfRGppZVpmaW9IaWEtSXFzMDVLc3QybFZPQnMyb2szcm0xeDB2UGNJeVQ1dUpEMlU4Sy0tamtsQ0lJV0Z4VGc4WFdkcjJTN0VJa1RhRXB6YWNNempmZURoRE95Y05ocktOeEFOeHdtcHkwT3d5NnYwTmNDNjNDVUFERkRNTk9BOVp6cU1SSmk0YUNKQQ?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Epilepsy Clinical Trial Pipeline Appears Robust With 75+ Key - openPR.com","headline":"Epilepsy Clinical Trial Pipeline Appears Robust With 75+ Key","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":1,"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}